Development and validation of a LC/MS/MS method for 6-keto PGF1α, a metabolite of prostacyclin (PGI2)
Authors:
- 1 November 2011
- journal article
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 56 (3) , 600-603
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Selective thromboxane inhibition after vascular protectant AGI-1067: results of assessment of lipoprotein profiles (ALPS) biomarkers in vitro and in vivo substudyJournal of Thrombosis and Thrombolysis, 2008
- Comparative Inhibitory Activity of Etoricoxib, Celecoxib, and Diclofenac on COX‐2 Versus COX‐1 in Healthy SubjectsThe Journal of Clinical Pharmacology, 2008
- Balancing prostanoid activity in the human vascular systemTrends in Pharmacological Sciences, 2007
- Prostaglandin I2 release following mesenteric traction during abdominal surgery is mediated by cyclooxygenase-1European Journal of Pharmacology, 2006
- Comparative Inhibitory Activity of Rofecoxib, Meloxicam, Diclofenac, Ibuprofen, and Naproxen on COX‐2 versus COX‐1 in Healthy VolunteersThe Journal of Clinical Pharmacology, 2000
- Rapid solid-phase immunoassay for 6-keto prostaglandin F1 alpha on microplatesClinical Chemistry, 1990
- The clinical significance of inhibition of renal prostaglandin synthesisKidney International, 1987
- Estimated rate of prostacyclin secretion into the circulation of normal man.Journal of Clinical Investigation, 1981